Rathbones Group PLC raised its holdings in Becton, Dickinson and Company (NYSE:BDX – Free Report) by 17.9% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 17,890 shares of the medical instruments supplier’s stock after acquiring an additional 2,719 shares during the period. Rathbones Group PLC’s holdings in Becton, Dickinson and Company were worth $3,202,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors also recently added to or reduced their stakes in BDX. Maryland Capital Advisors Inc. lifted its holdings in shares of Becton, Dickinson and Company by 13,900.0% during the third quarter. Maryland Capital Advisors Inc. now owns 140 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 139 shares during the last quarter. Bell Investment Advisors Inc bought a new stake in shares of Becton, Dickinson and Company in the second quarter valued at approximately $29,000. Kelleher Financial Advisors bought a new stake in shares of Becton, Dickinson and Company in the second quarter valued at approximately $30,000. Trifecta Capital Advisors LLC grew its stake in shares of Becton, Dickinson and Company by 59.0% in the third quarter. Trifecta Capital Advisors LLC now owns 167 shares of the medical instruments supplier’s stock worth $30,000 after acquiring an additional 62 shares during the last quarter. Finally, Meeder Asset Management Inc. grew its stake in shares of Becton, Dickinson and Company by 153.5% in the third quarter. Meeder Asset Management Inc. now owns 180 shares of the medical instruments supplier’s stock worth $32,000 after acquiring an additional 109 shares during the last quarter. 86.97% of the stock is owned by institutional investors.
Becton, Dickinson and Company Trading Down 0.2%
Becton, Dickinson and Company stock opened at $212.19 on Friday. The business has a 50 day moving average price of $194.40 and a two-hundred day moving average price of $170.85. The company has a quick ratio of 0.54, a current ratio of 0.87 and a debt-to-equity ratio of 0.54. Becton, Dickinson and Company has a 12 month low of $140.11 and a 12 month high of $220.36. The stock has a market cap of $58.47 billion, a price-to-earnings ratio of 51.25, a price-to-earnings-growth ratio of 3.56 and a beta of 0.22.
Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The medical instruments supplier reported $4.15 earnings per share for the quarter, topping the consensus estimate of $4.07 by $0.08. Becton, Dickinson and Company had a return on equity of 14.90% and a net margin of 5.66%. The company had revenue of $5.27 billion for the quarter, compared to analyst estimates of $5.11 billion. During the same quarter last year, the firm earned $3.96 EPS. Becton, Dickinson and Company’s revenue for the quarter was up 5.4% compared to the same quarter last year. As a group, equities analysts forecast that Becton, Dickinson and Company will post 13.21 EPS for the current year.
Becton, Dickinson and Company announced that its Board of Directors has authorized a stock repurchase plan on Thursday, November 5th that allows the company to buy back 10,000,000 shares. This buyback authorization allows the medical instruments supplier to reacquire up to 3.6% of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s leadership believes its stock is undervalued.
Becton, Dickinson and Company Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Thursday, December 31st. Investors of record on Thursday, December 10th will be paid a $1.06 dividend. The ex-dividend date is Thursday, December 10th. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $1.05. This represents a $4.24 dividend on an annualized basis and a dividend yield of 2.0%. Becton, Dickinson and Company’s dividend payout ratio is currently 101.45%.
Insider Buying and Selling at Becton, Dickinson and Company
In other Becton, Dickinson and Company news, EVP Michael Feld sold 165 shares of the business’s stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total value of $31,100.85. Following the sale, the executive vice president owned 19,720 shares of the company’s stock, valued at $3,717,022.80. The trade was a 0.83% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,993 shares of the business’s stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $210.00, for a total transaction of $628,530.00. Following the completion of the sale, the chief executive officer directly owned 110,163 shares in the company, valued at $23,134,230. This trade represents a 2.65% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 3,310 shares of company stock valued at $688,650. 0.40% of the stock is owned by company insiders.
Analysts Set New Price Targets
A number of equities analysts recently issued reports on BDX shares. Stifel Nicolaus set a $195.00 target price on shares of Becton, Dickinson and Company in a research report on Friday, August 7th. Piper Sandler increased their price target on shares of Becton, Dickinson and Company from $175.00 to $200.00 and gave the company a “neutral” rating in a report on Friday, November 6th. UBS Group assumed coverage on shares of Becton, Dickinson and Company in a report on Tuesday, July 28th. They issued a “buy” rating and a $190.00 price target for the company. Wolfe Research initiated coverage on shares of Becton, Dickinson and Company in a research report on Tuesday, October 20th. They issued an “outperform” rating on the stock. Finally, Bank of America boosted their price objective on shares of Becton, Dickinson and Company from $185.00 to $200.00 and gave the stock a “neutral” rating in a report on Monday, August 31st. Eight analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $197.47.
Check Out Our Latest Analysis on Becton, Dickinson and Company
About Becton, Dickinson and Company
Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops and manufactures products used in healthcare, clinical laboratories and life sciences research. Founded in 1897, the company has a long history of producing medical devices and supplies. BD’s products include syringes, needles, infusion systems and medication-management technologies, as well as equipment and supplies for collecting and processing clinical specimens. The company also provides diagnostic systems, laboratory instruments and tools used in areas such as cell analysis and biomedical research.
Featured Stories
- Five stocks we like better than Becton, Dickinson and Company
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.
